BG
IOVA icon

Bellevue Group’s Iovance Biotherapeutics IOVA Stock Holding History

Bellevue Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16,000
Closed -$142K – 142
2018
Q4 		$142K Sell
16,000
-9,000
-36% -$86.8K 0.01% 138
2018
Q3 		$281K Buy
+25,000
New +$355K 0.02% 138

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group's IOVA Position: Q1 2019 in Review

Bellevue Group sold out of Iovance Biotherapeutics (IOVA) in Q1 2019, closing a stake of 16,000 shares — an estimated $142K sold.

Bellevue Group first reported a position in IOVA in Q3 2018 and held it in 2 quarters. The position peaked at $281K in Q3 2018. 153 funds tracked by Wall St. Rank hold IOVA as of Q1 2019.

  • Bellevue Group reported no remaining Iovance Biotherapeutics position as of Q1 2019 after selling out during the quarter.
  • Bellevue Group sold 16,000 Iovance Biotherapeutics shares in Q1 2019, an estimated $142K.
  • Bellevue Group first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 2 quarters.
  • Bellevue Group's Iovance Biotherapeutics position peaked at $281K in Q3 2018.
  • 153 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2019.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.